Precipart Receives Investment from KKR to Accelerate Growth

KKR has agreed to invest in Precipart, a leading contract manufacturer of precision components for the medical device and aerospace industries, to support its continued organic and M&A growth, without disclosing financial terms.

KKR is investing in Precipart through its Health Care Strategic Growth Fund II, a $4.0 billion fund focused on investing in high-growth healthcare related companies. KKR has a long track record of supporting healthcare companies globally, having committed over $20 billion to the sector since 2004.

Founded in 1950 by the Laubscher family, Precipart manufactures highly engineered custom components, offering a comprehensive solution across design, engineering, manufacturing, and assembly for leading Original Equipment Manufacturers (“OEM”). In particular, the Company is a global leader in gears and motion control solutions across a range of end market segments, including surgical robotics. The Laubscher family remains highly committed to Precipart and is retaining a significant minority ownership stake in the Company.

With KKR’s differentiated industry expertise, global network and deep bench of resources, Precipart will be able to significantly expand its capabilities to serve customers better and at scale,” said Oliver Laubscher, CEO of Precipart.

We believe Precipart has the fundamental strength and customer focus to become a global platform and are excited to partner with the company on its growth ambitions,” said Ali Satvat, Partner and Global Head of Health Care Strategic Growth at KKR.

The medical device market is in need of sophisticated, scaled solution providers that can help customers navigate supply chain complexity, and we believe that Precipart is uniquely positioned to become a best-in-class partner for medical device OEMs,” added Anuv Ratan, Director at KKR.

To view the source version, please click HERE.